News | October 07, 2007

DES Effective in High Risk Angioplasty Patients'

October 8, 2007 - Drug-eluting stents were found to be most effective in reducing the need for repeat angioplasty procedures or bypass surgery in angioplasty patients at the ‘highest risk for a renarrowing of the artery around the stent, without significantly increasing the rate of death or risk of heart attack, said a new study by Ontario’s Institute for Clinical Evaluative Sciences (ICES) and McMaster University’s Program for Assessment of Technologies in Health.

Lead Author, ICES Sr. Scientist, Jack Tu, M.D., said, “Our results also suggest physicians should be selective in using drug-eluting stents, offering them to angioplasty patients who are at the highest risk for repeat cardiac procedures.”

Reporting in the October 4th issue of the New England Journal of Medicine, the large Canadian study conducted at ICES, in collaboration with cardiologists and researchers from Sunnybrook Health Sciences Centre and the University of Toronto, looked at over 3,700 unique matched pairs of Ontario patients who received drug-eluting stents (DES) or more conventional bare metal stents (BMS) during angioplasty. Using data from the Ontario Cardiac Care Network's (CCN) population-based angioplasty registry, and accounting for differences in patient characteristics, investigators analyzed the outcomes of patients having angioplasty in Ontario between December 2003 and March 2005 for the 'real-world' effectiveness of DES. The results:

- DES reduced the need for a second procedure to unblock or bypass a clogged artery by 30 percent relative to BMS, from 10.7 percent to 7.4 percent.
- After three years of follow up, mortality was reduced for DES patients (5.5 percent) relative to BMS (7.8 percent).
- After two years of follow up, rate of heart attack for DES patients was marginally but not significantly higher at 5.7 percent vs. 5.2 percent in BMS patients.
- The reduction in the need for repeat procedures (i.e. target vessel revascularization (TVR rate)) was greatest in patients with two or three risk factors (e.g. diabetes, small vessels, or long lesions) for renarrowing of the artery, whereas lower and intermediate risk patients did not have significant reductions in TVR rates.

Author affiliations: ICES (J.V.T., M.C., D.T.K., P.C.A., Y.H.) and Sunnybrook Health Sciences Centre, University of Toronto (J.V.T., D.T.K., E.A.C.) - both in Toronto; McMaster University, St. Joseph's Healthcare, Hamilton, ON (J.B., R.H., J.-E.T., G.B., R.G.); and Trillium Health Centre, Mississauga, ON, (C.L.) - all in Canada.

Source: Institute for Clinical Evaluative Sciences

For more information: www.ices.on.ca

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init